Cloron

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cloron

Property Description
Active ingredient Clonazepam
Form Tablet, Oral Solution
Pharmacological class Benzodiazepine, Anticonvulsant
General purpose Stabilizing excessive nerve activity
Origin Synthetic compound

Cloron is a prescription-only medication whose active ingredient is Clonazepam, a synthetic compound that is chemically defined as a Benzodiazepine derivative. It is classified as a Central Nervous System (CNS) Depressant and functionally as an Anticonvulsant or Antiepileptic Drug (AED). This medication is fundamentally characterized by its specific chemical structure and pharmacological action, which targets pathways in the brain to reduce excessive electrical activity. The drug is manufactured as a single-ingredient product, meaning Clonazepam is the only component responsible for the therapeutic effect.


What Chemical Class Does It Belong To?

Clonazepam belongs to the benzodiazepine class, a group of psychoactive compounds known for their distinct molecular structure and inhibitory effects on the nervous system. This classification places it among potent medications that act on the brain to modulate neurotransmission. In the context of use, the medication is categorized as an Anticonvulsant, a role clinically recognized for managing conditions such as certain types of seizure disorders. As a potent CNS depressant, the medicine works by slowing down signals in the central nervous system. For oral administration, Cloron is typically supplied as a solid tablet or, less frequently, as an oral solution.


What Is the General Purpose of This Benzodiazepine Derivative?

The general purpose of Clonazepam is to stabilize states of excessive brain excitability by enhancing the action of the brain's main inhibitory neurotransmitter, \gamma-aminobutyric acid (GABA). By binding to the GABA-A receptor, Clonazepam amplifies the natural "braking" signal, resulting in a generalized dampening of nerve cell activity across the CNS. The primary pharmacological action of Clonazepam is to increase inhibitory GABA neurotransmission. In simple terms, the medicine increases the brain’s ability to calm itself. This potent inhibitory action provides the foundation for the drug's role in managing conditions characterized by hyperexcitable neural pathways, which translates to a stabilizing and calming influence on the nervous system, such as in the control of chronic anxiety.

What side effects are possible with Cloron?

Possible side effects and safety information

Cloron's official safety profile, as documented by regulatory agencies, is characterized by effects related to its action as a Central Nervous System (CNS) depressant. The most frequently observed adverse reactions are classified as Very Common or Common and often occur early in treatment.

Adverse Reaction Categories and Frequency

The most common effects are primarily categorized under Nervous System Disorders and General Disorders.

Classification Examples of Officially Listed Reactions
Very Common Drowsiness, Somnolence
Common Ataxia (unsteadiness), Fatigue, Dizziness, Dysarthria (slurred speech)
Rare Angioedema, Blood dyscrasias, Liver function abnormalities

Common effects like somnolence and ataxia are typically transient, often lessening or disappearing with continued treatment or dose adjustment. Conversely, long-term exposure carries the risk of developing tolerance and physical dependence.

Serious Safety Considerations

Official labeling includes serious warnings concerning the potential for abuse, misuse, addiction, and the risk of life-threatening acute withdrawal reactions if the medication is abruptly stopped or rapidly reduced. The concomitant use of Clonazepam and opioids significantly increases the risk of profound sedation, respiratory depression, coma, and death, a risk highlighted with a regulatory Boxed Warning in the United States. Additionally, like other Antiepileptic Drugs, Clonazepam may be associated with an increased risk of suicidal thoughts or behavior.

Population-Specific Notes

Regulatory documents highlight that older adults are more susceptible to CNS depressant effects, increasing the risk of confusion, severe drowsiness, and falls. The drug is contraindicated in patients with clinical evidence of significant liver disease.

Overdose and Emergency Response

Overdose and When to Seek Help

Cloron (referencing the regulatory profile of clonazepam) is a central nervous system (CNS) depressant. Overdose symptoms are classified by severity and primarily affect the CNS and respiratory system. Official sources document overdose presentations as somnolence, confusion, diminished reflexes, and coma (loss of consciousness). Serious consequences are rare with isolated ingestion but the risk is significantly increased when taken concomitantly with opioid medicines, alcohol, or other CNS depressants, which can lead to profound sedation, severe respiratory depression, coma, and death.

Required Emergency Actions

Immediate medical attention is required for any signs of overdose or if serious adverse effects occur. If you suspect an overdose, contact a Poison Control Center immediately. In critical situations, immediately call emergency services (911) if the individual has collapsed, has had a seizure, exhibits slowed or difficult breathing, or is unresponsive and cannot be awakened. Timely emergency intervention is crucial to manage respiratory compromise.

Therapeutic Uses of Cloron

The therapeutic use of Cloron (Clonazepam) is relevant in managing symptoms across specific neurological and psychiatric domains. This approach is typically applied in conditions where heightened neurological activity may cause disruptive or overwhelming symptoms.


What Cloron Treats: Main Uses and Benefits

Cloron is commonly used to help with symptom clusters that may become intense, such as in specific epilepsy syndromes, including Lennox-Gastaut syndrome, akinetic seizures, and myoclonic jerks. The medication is also applicable within clinical settings that involve acute or disruptive symptom patterns, such as the heightened distress of Panic Disorder. Additionally, it is relevant for managing symptoms that create noticeable functional strain, such as persistent muscle spasms and the severe, disruptive restlessness of Restless Legs Syndrome.

This supportive symptomatic management is commonly used for conditions characterized by periods of heightened symptoms, contributing to relief for their frequency and intensity, and helping patients cope more steadily with acute or recurrent episodes.


Quick Fact: Symptomatic Relief for Acute Panic Attacks

Cloron assists with managing physical symptoms that appear suddenly, including palpitations, trembling, and overwhelming fear, often applied in settings where short-term symptomatic assistance is needed during episodic occurrences.

Eligibility and Restrictions for Use

Eligibility Scope

Official regulatory documentation defines eligibility for Cloron based on patient age, reproductive status, and specific pre-existing conditions. Use is established for adults and pediatric patients for seizure disorders, and for adults only for panic disorder. Conversely, use is not established for panic disorder in patients under 18 years of age.

Category Official Regulatory Statement
Populations for whom use is contraindicated History of sensitivity to benzodiazepines; significant liver disease; or acute narrow-angle glaucoma.
Pregnancy and lactation eligibility Not recommended; the drug is excreted in human milk, and a decision must be made to either discontinue the medication or discontinue breastfeeding.
Eligibility-related restrictions Caution is advised for geriatric patients due to potential increased sensitivity. Caution is also required for patients with renal impairment, lung/breathing problems, or a history of drug/alcohol dependence.

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use Cloron by setting absolute contraindications based on allergic history, organ function, and specific eye conditions. The profile also sets age-based exclusions for certain uses and outlines conditional use or caution for populations with compromised organ function or those with a history of substance abuse.

What should I know about interactions with other medicines?

The interaction profile of Cloron (Clonazepam) is officially defined by its central nervous system activity and its metabolic pathway involving the CYP3A4 enzyme.


Pharmacodynamic Reinforcement and Restrictions

Co-administration with Opioid medications is formally warned against by regulatory bodies due to the potential risk of profound sedation, respiratory depression, coma, and death. The use of Alcohol is also strictly advised against due to the severe potential for additive CNS depression and unpredictable alteration of the medicine's effects. Concurrent use with general CNS-Depressant drugs (including many Antidepressants, Antipsychotics, Hypnotics, and other Antiepileptic Drugs) results in additive CNS depression due to pharmacodynamic synergism.


Pharmacokinetic Interference

Clonazepam clearance is mediated by the CYP3A4 enzyme. CYP3A4 Inducers (such as Carbamazepine, Phenytoin, and Phenobarbital) are associated with a reduction in Clonazepam plasma concentration by increasing its metabolic clearance. Conversely, CYP3A4 Inhibitors (such as Clarithromycin, Itraconazole, and Ketoconazole) may lead to a significant increase in the serum concentration of Clonazepam by decreasing its clearance rate. No specific mandatory time-separation rules are documented for co-administered medicines.


Population-Specific Considerations

Interaction risks may be higher in patients with significant hepatic impairment because the drug's hepatic metabolism is compromised, potentially leading to drug accumulation. Older adults and children are also noted in regulatory summaries as being more prone to the adverse effects of the medicine.

Mechanism of Action

Modulating GABA-A Receptor Activity

Cloron acts as a positive allosteric modulator of GABA-A receptors in the central nervous system. This molecular engagement enhances the activity of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). The key pathway effect is an increase in the frequency of chloride ion channel opening, leading to the hyperpolarization of neurons. This increased inhibition results in reduced neuronal excitability and firing rate throughout the central nervous system.


️ Influencing Serotonin Pathway Dynamics

Beyond its primary target, Cloron is also associated with a secondary, modulatory mechanistic domain involving the neurotransmitter serotonin (5-HT). It has been shown to decrease the utilization of 5-HT by neurons and to bind tightly to central-type benzodiazepine receptors. This pathway influence contributes to the drug's overall effect profile by further regulating complex neurobiological processes and modulating the balance of excitatory and inhibitory signaling within targeted systems.

Dosage and Administration Information

Cloron is primarily administered by the oral route, utilizing a standard tablet, an oral solution, or an orally disintegrating tablet (ODT). A parenteral solution is officially approved for intravenous (IV) use in acute clinical settings. For oral administration, the medication may be taken with or without food. Standard tablets should be swallowed whole with water, though certain forms are scored to permit dose division. The Orally Disintegrating Tablet requires specific handling instructions, including the use of dry hands, and must not be split, crushed, or chewed.

The administration protocol begins with a low initial dose to establish patient response. For adult seizure disorders, treatment typically starts at 1.5 mg per day, administered in divided doses. The dose is then increased slowly, or titrated, by increments of 0.5 mg to 1 mg every three days until a therapeutic maintenance dose is reached, up to a maximum of 20 mg per day. For panic disorder, the initial dose is 0.25 mg taken twice daily, with a maximum dose of 4 mg per day.

Initial treatment involves divided daily doses; however, the total daily amount may be consolidated into a single dose, often taken in the evening, once maintenance is achieved. Dosage adjustments are required for specific patient populations; for instance, the starting dose for older adults should generally not exceed 0.5 mg per day. A mandated procedural step is the gradual discontinuation of the medication. The dose must never be stopped abruptly, but rather tapered slowly, such as by reducing the dose by 0.125 mg twice daily every three days.

Recent Clinical Evidence

Research evidence / Overview of studies for Cloron

This section provides a summary of the available research evidence for Clonazepam, focusing only on the types of studies that exist, what they measured, and what remains uncertain, based on official regulatory and peer-reviewed scientific sources.


Evidence for Use in Epilepsy Syndromes (Lennox-Gastaut Syndrome and Myoclonic Seizures)

Clonazepam was studied for use in conditions characterized by unstable or episodic manifestations, particularly specific seizure disorders like Lennox-Gastaut syndrome (LGS), akinetic seizures, and myoclonic seizures. Research examining LGS typically involved randomized controlled trials (RCTs) where the medicine was applied as an addition to existing treatment. These studies explored short-term symptom changes by monitoring the frequency of drop seizures and tracking patient progress through physician or caregiver assessments.

Studies conducted during periods of increased symptom activity reported measurements of observed changes in the frequency of drop seizures during the relatively short duration of controlled trials. Long-term observational data described patterns related to continued use. For myoclonic seizures, research has included meta-analyses that synthesized data from various clinical studies, which examined outcomes related to changes in the frequency of jerks and the proportion of individuals who achieved a seizure-free status during the observation period. Findings describe patterns observed in the studied populations of children and adolescents with these specific epilepsy syndromes.


Evidence for Use in Panic Disorder

The research base for Clonazepam's use in Panic Disorder is supported by short-term, randomized, double-blind, placebo-controlled trials (RCTs) conducted in adults diagnosed with the condition. These studies focused on acute or disruptive episodes, monitoring outcomes describing episodic or acute changes in symptom patterns. The primary outcomes measured included the weekly frequency of full panic attacks and global scales that assessed the severity of anticipatory anxiety and phobic avoidance.

In these acute-phase studies, research highlights changes measured during the study period related to the frequency of panic attacks when compared against placebo. Findings also described patterns related to changes in measured anxiety severity and related functional outcomes over the course of the trials, which generally lasted between six and nine weeks.


What Research Gaps and Uncertainties Remain

Official research and regulatory reviews identify several areas where data remain insufficient or certainty remains low. The primary research limitation is the availability of long-term, controlled data for many indications, especially Panic Disorder, where follow-up durations were limited. For epilepsy, the concern for the development of tolerance means that the durability of observed symptom patterns is an area where research provides context but does not determine individual outcomes. Overall, while research describes patterns related to short-term changes, the evidence quality varies across studies, and there is a need for more robust, modern comparative evidence across all approved uses.

Frequently Asked Questions (FAQ)

Common questions about Cloron (FAQ)


Q: What is Cloron used for?

A: Cloron is indicated for the management of symptoms associated with certain chronic inflammatory conditions, as determined by a healthcare professional. Its use is based on its classification as a selective antagonist.

Q: How should I store Cloron?

A: Storage instructions typically require keeping Cloron tablets at room temperature, away from moisture and heat. It is important to keep the medication in its original container and out of the reach of children. Refer to the specific product labeling for precise details.

Q: What should I do if I miss a dose of Cloron?

A: If a dose is missed, it is generally advised to take the missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Patients should not take two doses at the same time to make up for a missed dose. It is recommended to discuss how to handle missed doses with the prescribing physician or pharmacist.

Q: Can Cloron be taken with other medications?

A: Cloron may interact with other prescription and over-the-counter medicines, vitamins, and herbal products. Potential interactions could affect how Cloron works or increase the risk of side effects. It is essential to provide a complete list of all current medications to a healthcare provider for review before starting Cloron.

Q: How long does it take for Cloron to start working?

A: The time it takes to observe potential symptomatic changes or benefits from Cloron can vary widely among individuals and depends on the condition being managed. Some people may notice effects within a few weeks, while for others, it may take longer. Continuing the treatment as prescribed and regularly communicating with a healthcare provider is recommended to assess its effectiveness.

How should Cloron be stored and disposed of?

Storage and Disposal of Clonazepam (Cloron)

Clonazepam tablets must be stored at controlled room temperature, typically between 20°C and 25°C (68°F and 77°F). The medication must be protected from light and moisture. To ensure stability, keep the tablets in their original container and make sure it is tightly closed.


Security and Disposal Rules

Clonazepam is a Schedule IV controlled substance. Due to its classification, it must be kept out of the reach and sight of children, and storing it in a locked location is recommended to prevent misuse.

For disposal, do not flush unused or expired tablets down the toilet. Follow official guidelines by utilizing a drug take-back program or securely disposing of the product in household trash after mixing it with an undesirable substance, such as coffee grounds.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cloron found in:

A-Z Index: